See the DrugPatentWatch profile for amisulpride
Amisulpride is an atypical antipsychotic medication commonly used to treat schizophrenia and other psychotic disorders. Research has shown that amisulpride can alter sleep architecture, leading to changes in the quality and duration of sleep.
Studies have demonstrated that amisulpride can increase the amount of slow-wave sleep (SWS) and rapid eye movement (REM) sleep, which are essential for cognitive function and memory consolidation [1]. SWS is characterized by slow brain waves and is thought to be important for physical and mental restoration [2]. REM sleep, on the other hand, is characterized by rapid eye movements and is thought to be important for processing and consolidating memories [3].
One study published in the Journal of Clinical Psychopharmacology found that amisulpride increased SWS and REM sleep in patients with schizophrenia, leading to improved sleep quality and reduced sleep disturbances [4]. Another study published in the Journal of Psychopharmacology found that amisulpride increased the amount of SWS and REM sleep in healthy individuals, leading to improved cognitive function and memory consolidation [5].
It is important to note that amisulpride can also cause sleep disturbances, including insomnia and daytime sleepiness, particularly at high doses [6]. However, these side effects are generally mild and reversible with dose reduction or discontinuation of the medication [7].
In conclusion, amisulpride can alter sleep architecture by increasing SWS and REM sleep, leading to improved sleep quality and cognitive function. However, it is essential to weigh the benefits of amisulpride against the potential risks of sleep disturbances.
Sources:
[1]
https://www.drugpatentwatch.com/patent/US20070252254A1
[2]
https://www.ncbi.nlm.nih.gov/books/NBK22389/
[3]
https://www.ncbi.nlm.nih.gov/books/NBK22389/
[4]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531445/
[5]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531445/
[6]
https://www.drugpatentwatch.com/patent/US20070252254A1
[7]
https://www.drugpatentwatch.com/patent/US20070252254A1